On October 30, Stryker recorded an Overnight fall of 10.51%, trading at $277.0 per share, after the company released quarterly results and updated its full-year outlook.
The clearest catalyst was an earnings-driven reset: third-quarter adjusted EPS came in at $3.52, below the $3.55 consensus, while revenue rose to $6.52 billion from $6.06 billion but missed the $6.62 billion expectation. More importantly, Stryker lowered its full-year adjusted EPS guidance to $14.80-$14.90 from the prior $14.95-$15.10 range, versus a $14.95 analyst expectation.
The company also increased its share repurchase authorization by $3 billion, but that capital return step did not offset investor concern over the guidance reduction and the quarterly top- and bottom-line shortfall.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments